Abstracts will include updates on treatment for psoriatic arthritis, psoriasis, atopic dermatitis, and more.
AbbVie Inc. will present 23 abstracts at the 31st European Academy of Dermatology and Venerology (EADV) Congress in Milan, virtually and in-person, in September 2022. Data presented at the congress will provide dermatologic clinicians with studies and results regarding immune-mediated skin diseases such as psoriatic arthritis, psoriasis, atopic dermatitis, and vitiligo.1
Some of the most notable discussions will include data on:
Overall, AbbVie will present 8 abstracts about risankizumab for psoriasis, 6 abstracts about risankizumab for psoriatic arthritis, and 3 abstracts about upadacitinib (RINVOQ; AbbVie) for atopic dermatitis. Regarding disease states, AbbVie will include 6 disease state abstracts covering psoriasis, atopic dermatitis, and vitiligo.
The 2022 EADV Congress will include over 600 presenters and over 170 sessions.2 To reach as many participants as possible, the congress will feature hybrid sessions that are both in-person and live-streamed. Recorded sessions will be available for viewing for 3 months after the congress. The full EADV 2022 schedule can be found here.